List of Excipients in Branded Drug DEPAKOTE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	DEPAKOTE	divalproex sodium	0074-3826	CELLULOSE, MICROCRYSTALLINE
AbbVie Inc	DEPAKOTE	divalproex sodium	0074-3826	FD&C BLUE NO. 1
AbbVie Inc	DEPAKOTE	divalproex sodium	0074-3826	HYPROMELLOSE
AbbVie Inc	DEPAKOTE	divalproex sodium	0074-3826	LACTOSE
AbbVie Inc	DEPAKOTE	divalproex sodium	0074-3826	POLYETHYLENE GLYCOL
AbbVie Inc	DEPAKOTE	divalproex sodium	0074-3826	POTASSIUM SORBATE

Depakote Excipient Strategy and Commercial Opportunities

Last updated: September 21, 2026

Depakote is the branded divalproex sodium product marketed by AbbVie for epilepsy, bipolar disorder and migraine prophylaxis. Its active ingredient has no meaningful remaining composition-of-matter exclusivity in the United States. Commercial opportunity is concentrated in excipient-enabled differentiation: delayed release, extended release, sprinkle delivery, dose flexibility, tolerability, pediatric administration and manufacturing efficiency.

The strongest opportunity is not a new excipient alone. It is a reproducible formulation platform that controls valproate release, limits gastrointestinal exposure, supports smaller tablets or sprinkle dosing, and generates a defensible regulatory package under an abbreviated or 505(b)(2) pathway.

What is Depakote and which dosage forms use different excipient strategies?

Depakote contains divalproex sodium, a compound formed from sodium valproate and valproic acid. FDA-approved Depakote presentations include delayed-release tablets, delayed-release sprinkle capsules and extended-release tablets. Each form uses a different release-control strategy.[1]

Product	Dosage form	Primary formulation objective	Commercial relevance
Depakote	Delayed-release tablet	Prevent release in the stomach and deliver valproate in the intestine	Direct generic competition
Depakote Sprinkle	Delayed-release capsule containing particles	Permit administration by sprinkling on soft food while preserving enteric protection	Pediatric and dysphagia opportunity
Depakote ER	Extended-release tablet	Reduce dosing frequency and smooth plasma exposure	Higher-value modified-release segment
Generic divalproex sodium	Delayed-release and extended-release products	Match reference-product quality and bioequivalence	Large price-driven market

Delayed-release products generally rely on enteric coating technology. Extended-release products require matrix, coating or multilayer systems that control drug release over a longer period. Depakote Sprinkle adds a multiparticulate delivery requirement: each particle must maintain adequate dose uniformity, enteric protection and release performance after administration with food.

What excipients are used in Depakote formulations?

The exact inactive-ingredient profile varies by dosage form and manufacturing presentation. FDA labeling identifies inactive ingredients for each approved product, while the FDA Inactive Ingredient Database provides precedent for excipient use by route and dosage form.[1][2]

Common functional excipient categories relevant to Depakote include:

Excipient function	Typical materials or material classes	Role in divalproex products
Diluent or filler	Microcrystalline cellulose, lactose or related fillers	Tablet mass, compressibility and content uniformity
Binder	Povidone and cellulose derivatives	Granule and tablet mechanical strength
Disintegrant	Crospovidone, croscarmellose sodium or starch derivatives	Breakup of the core after coating rupture
Lubricant and glidant	Magnesium stearate, colloidal silicon dioxide	Compression and powder-flow control
Enteric polymer	Methacrylic acid copolymers, cellulose acetate phthalate or similar polymers	Protection from gastric release
Film former	Hypromellose and related cellulose polymers	Mechanical coating integrity and release control
Plasticizer	Polyethylene glycol, triethyl citrate or similar agents	Flexibility and reduced coating brittleness
Opacifier and colorant	Titanium dioxide, iron oxides and approved colorants	Appearance, light protection and product identification
Capsule shell	Gelatin or hypromellose	Delivery of delayed-release particles
Anti-tacking agent	Talc or colloidal silicon dioxide	Coating-process control

The commercial importance of an excipient depends on its function, not its presence on the ingredient list. A standard filler rarely creates meaningful differentiation. An enteric polymer system, multiparticulate coating architecture or release-controlling matrix can affect bioequivalence, stability, manufacturing cost and patent scope.

Which excipient functions create the strongest commercial opportunities?

Modified-release control

The highest-value formulation work concerns release control. Valproate products require predictable exposure because changes in absorption rate can affect tolerability, dosing frequency and clinical substitution.

Potential platforms include:

• pH-dependent enteric coatings for delayed release.
• Hydrophilic matrix systems for extended release.
• Insoluble or semi-permeable membrane coatings.
• Multiparticulate beads or granules.
• Coated mini-tablets compressed into a larger unit.
• Bilayer or multilayer tablets with separate immediate- and extended-release zones.

The key development metric is not simply dissolution at one time point. It is a full release profile across acidic and intestinal media, with robustness against food effects, compression force, coating weight and storage conditions.

Sprinkle and pediatric delivery

Depakote Sprinkle addresses patients who cannot swallow tablets. A next-generation formulation could improve:

• Dose flexibility.
• Particle size and mouthfeel.
• Food compatibility.
• Reduced powder adhesion to containers or utensils.
• Reduced exposure to valproate odor or taste.
• Stability after opening.
• Administration through feeding tubes.

Taste masking is a substantial opportunity. Valproate products can have an unpleasant taste and odor, which can reduce adherence, particularly in pediatric and neurologically impaired populations. Candidate approaches include polymeric taste barriers, lipid or wax coatings, ion-exchange resins, lipid microparticles and flavor systems compatible with enteric protection.

The formulation must preserve delayed release after sprinkling. A taste-masked particle that releases prematurely in the mouth or stomach would create both performance and regulatory problems.

Lower pill burden and dose flexibility

Depakote ER is positioned around once-daily administration. A commercial formulation can compete through smaller unit strength, scored tablets, divisible multiparticulates or flexible dosing combinations.

A smaller tablet is valuable only if it maintains:

• Dose uniformity.
• Mechanical strength.
• Coating integrity.
• Dissolution performance.
• Stability under humidity and temperature stress.

Reducing tablet size through higher drug loading may create manufacturability problems because divalproex sodium has demanding flow, compression and coating requirements. Excipient selection therefore has a direct impact on plant throughput and cost of goods.

What patents protect Depakote formulations?

The core divalproex sodium composition is no longer a meaningful barrier to generic entry. The principal U.S. patent risk historically centered on dosage-form and release technology rather than the active ingredient.

Patent category	Relevance to Depakote	Current commercial effect
Divalproex sodium composition patents	Covered the active compound or compound combination	Largely expired
Delayed-release formulation patents	Covered enteric protection and intestinal delivery	Historical importance; generally expired or limited
Extended-release formulation patents	Covered once-daily release profiles and dosage forms	Historical ANDA litigation relevance
Sprinkle or multiparticulate patents	Covered coated particles and administration with food	May affect specific follow-on designs depending on claim scope
Method-of-use patents	Covered epilepsy, bipolar disorder or migraine treatment	Limited value where claims have expired or are carved out
Manufacturing patents	Covered granulation, coating or processing steps	Potentially relevant to platform licensing and freedom-to-operate

The original Depakote estate was associated with Abbott Laboratories, later part of AbbVie. Historical U.S. patents covering divalproex sodium and modified-release products are generally beyond their ordinary patent terms. The Orange Book remains the controlling source for current listed patents and exclusivity for FDA-approved products.[3]

A formulation developer should not assume that an expired reference-product patent eliminates all risk. A new product may implicate:

• Later-issued formulation patents.
• Process patents.
• Particle engineering claims.
• Coated multiparticulate claims.
• Combination-product claims.
• Foreign patents with longer or different terms.
• Trade-secret manufacturing processes.

What is the Orange Book status of Depakote?

FDA’s Orange Book identifies approved drug products, therapeutic-equivalence evaluations, patents and regulatory exclusivity. Depakote products have faced extensive generic competition, and FDA-approved generic divalproex sodium products are listed in multiple dosage forms.[3]

The practical Orange Book position is:

1. Active-ingredient exclusivity is not the principal barrier.
2. Generic substitution is established for conventional delayed-release products where therapeutic equivalence has been assigned.
3. Extended-release and sprinkle products require product-specific bioequivalence and dissolution evidence.
4. A generic applicant must address listed patents through certification or a section viii statement, depending on the patent claim.
5. An excipient change can trigger additional comparative studies even when the active ingredient and strength are unchanged.

For a new delayed-release or extended-release product, Orange Book listing is not automatic. A product must first obtain FDA approval, and the sponsor must meet applicable requirements for patent certification and drug-product information.

When does Depakote lose exclusivity, and what does that mean for generic entry?

Depakote has already lost the exclusivity that protected its core commercial franchise. Generic entry is therefore a current-market condition, not a future event.

Paragraph IV challenges

Paragraph IV challenges historically provided a route for ANDA applicants to contest listed patents before patent expiration. A Paragraph IV certification can trigger Hatch-Waxman litigation and, in some cases, a 30-month stay of FDA approval.[4]

For Depakote, the highest-value Paragraph IV targets were formulation patents covering:

• Extended-release dosage forms.
• Release profiles.
• Once-daily administration.
• Enteric-coated particles.
• Sprinkle delivery.

The commercial importance of a Paragraph IV challenge declines after relevant patents expire or are delisted. At that point, the focus shifts to approval timing, manufacturing capacity, supply reliability and market share capture.

Generic launch scenarios

Scenario	Likely market effect
Additional delayed-release tablet entrant	Price erosion and substitution pressure
Additional extended-release entrant	Lower pricing, but slower share conversion because of product-specific substitution rules
Sprinkle generic	Competition in pediatric and swallowing-impaired populations
Authorized generic	Faster price pressure with reference-product manufacturing or licensing support
505(b)(2) reformulation	Potential premium pricing if delivery, adherence or tolerability improves
Nonprescription or supplement positioning	Generally unsuitable because valproate requires prescription oversight and carries serious safety risks

A generic launch does not require the same excipients as Depakote. It requires a formulation that meets FDA quality and bioequivalence standards. This creates room for lower-cost excipient systems, provided they produce a comparable in vivo and in vitro performance profile.

How strong is the patent estate for Depakote excipients?

The patent estate is weak around commodity excipients and stronger around integrated formulation systems.

Low-strength patent positions

These approaches usually provide limited exclusivity:

• Use of microcrystalline cellulose as a filler.
• Use of magnesium stearate as a lubricant.
• Use of standard hypromellose grades.
• Conventional film coating.
• Routine use of approved colors or opacifiers.
• Simple substitution of one common disintegrant for another.

Higher-strength patent positions

More defensible claims can arise from:

• A defined particle-size distribution.
• A specific coating-layer sequence.
• A narrow polymer ratio.
• A release profile tied to a dosing regimen.
• A low-dose or high-dose multiparticulate architecture.
• A taste-masking system that preserves delayed release.
• A manufacturing process that produces a defined dissolution signature.
• A formulation with reduced food effect.
• A stable formulation with reduced valproate degradation or odor.

The strongest claim strategy combines composition, process and performance limitations. A composition claim alone may be easier to design around. A process claim alone may be difficult to enforce without manufacturing evidence. A formulation defined by measurable dissolution and pharmacokinetic characteristics can provide stronger commercial relevance but must be supported by robust development data.

What formulation patents could support a new Depakote product?

A new patent program should focus on a specific unmet performance problem.

Candidate patent themes

1. A sprinkle formulation with improved taste masking and preserved enteric release.
2. A high-drug-load extended-release tablet with reduced tablet size.
3. A once-daily multiparticulate formulation with reduced food effect.
4. A low-variability formulation for patients receiving enteral feeding.
5. A formulation with improved humidity stability.
6. A coated particle system that supports dose titration without tablet splitting.
7. A valproate formulation with improved odor control.
8. A manufacturing process that reduces coating defects and batch variability.
9. A pediatric formulation with age-appropriate dose strengths.
10. A combination of enteric and extended-release layers that improves gastrointestinal tolerability.

A patent filing should include comparative data against Depakote and a representative generic. Useful evidence includes dissolution curves, fed and fasted pharmacokinetics, coating durability, taste-panel results, stability data, particle-size distribution and dose uniformity.

Which companies are challenging Depakote commercially?

Depakote faces competition from generic manufacturers rather than biosimilars. Valproate is a small molecule, so the relevant FDA pathway is ANDA approval, not a biosimilar application under the Public Health Service Act.

Generic competition has included manufacturers such as:

• Teva Pharmaceuticals.
• Mylan, now part of Viatris.
• Dr. Reddy’s Laboratories.
• Zydus Pharmaceuticals.
• Sun Pharmaceutical Industries.
• Lupin.
• Other ANDA holders listed in FDA product databases.

The competitive field varies by strength, dosage form and market period. Extended-release and sprinkle products typically have fewer qualified entrants than conventional delayed-release tablets because formulation development and bioequivalence are more demanding.

What FDA regulatory issues affect Depakote excipient changes?

FDA reviews excipient changes through the product’s regulatory pathway and the level of risk created by the change. A formulation that changes only inactive ingredients may still require substantial comparative evidence if the change affects release or absorption.

Critical regulatory issues include:

• Product-specific bioequivalence.
• Dissolution testing in multiple media.
• Food-effect assessment.
• Stability under ICH conditions.
• Dose proportionality.
• Content uniformity.
• Multiparticulate dose recovery.
• Administration with soft food.
• Feeding-tube compatibility.
• Pediatric acceptability.
• Extractables and leachables for packaging.
• Excipient qualification and supplier controls.

The FDA Inactive Ingredient Database can support excipient precedent, but database presence does not eliminate the need to justify concentration, function or safety in the proposed product.[2]

How does Depakote compare with competing valproate products?

Product class	Main advantage	Main weakness	Excipient opportunity
Delayed-release divalproex	Established generic availability	More frequent dosing and conventional tablet burden	Lower-cost enteric system, smaller tablet
Depakote ER and generic ER	Once-daily administration	More complex bioequivalence and release control	Reduced food effect and smoother release
Depakote Sprinkle and generic sprinkle	Flexible administration	Taste, odor and particle-handling problems	Taste masking, pediatric dosing and tube compatibility
Valproic acid liquid	Flexible dosing	Taste, measurement error and gastrointestinal tolerability	Palatability and dosing-device improvements
Sodium valproate products	Alternative salt presentation	Different markets and regulatory requirements	Salt selection, stability and modified release

The best commercial niche is a formulation that solves a use problem without requiring physicians to change the therapeutic choice. Pediatric sprinkle products, feeding-tube-compatible multiparticulates and smaller once-daily tablets have clearer differentiation than a conventional tablet with a different filler.

What licensing opportunities exist for Depakote excipient technology?

Licensing opportunities fall into four categories:

1. Excipient platform licensing for enteric or extended-release systems.
2. Contract development and manufacturing partnerships.
3. Generic formulation technology transfer.
4. 505(b)(2) product development with a differentiated delivery profile.

A platform owner can create value by licensing a validated coating process, taste-masking technology or high-drug-load matrix system to a generic manufacturer. The commercial package should include formulation know-how, analytical methods, scale-up parameters and comparative dissolution data.

A branded or specialty-pharma partner may pay more for a differentiated pediatric or adherence product than for a basic delayed-release generic. The value depends on regulatory exclusivity, patent term, payer acceptance and the ability to avoid direct price competition.

What revenue exposure does Depakote face from generic competition?

Revenue exposure is highest in conventional delayed-release tablets because multiple generic suppliers can manufacture the product and substitution is well established. Extended-release and sprinkle products can retain more value because formulation complexity limits entry and because patients may be less easily switched.

The main revenue drivers are:

• Generic count by strength and dosage form.
• Wholesaler and payer substitution.
• Brand loyalty among stable patients.
• Hospital and institutional purchasing.
• Shortages or recalls among generic suppliers.
• Pricing of extended-release products.
• Pediatric and specialty-prescribing concentration.
• Availability of authorized generic supply.

Excipient innovation can protect revenue only when it produces a clinically or operationally meaningful advantage. A change that is invisible to patients, prescribers and payers is likely to face rapid generic price competition.

Key Takeaways

• Depakote’s active-ingredient exclusivity is no longer the main commercial barrier.
• Excipient opportunity is concentrated in delayed release, extended release, sprinkle delivery, taste masking and dose flexibility.
• The strongest development targets are pediatric multiparticulates, feeding-tube-compatible products and smaller once-daily tablets.
• Commodity excipients provide little patent strength by themselves.
• Defensible patents should combine composition, process and measurable performance limitations.
• FDA approval depends on product-specific bioequivalence, dissolution, stability and administration data.
• Generic competition is established for divalproex sodium, but extended-release and sprinkle products remain more technically demanding.
• A licensing strategy is most attractive when it packages excipient technology with scale-up know-how and regulatory data.

FAQs

Is Depakote an excipient-protected drug?

No. Depakote’s commercial differentiation historically came from dosage-form technology, release control and brand positioning, not from exclusive ownership of a commodity excipient.

Can a generic use different excipients from Depakote?

Yes. An ANDA applicant generally may use different inactive ingredients if the product meets FDA requirements for quality, safety, performance and bioequivalence.

Is Depakote eligible for biosimilar competition?

No. Divalproex sodium is a small-molecule drug. Competition proceeds through generic drug pathways, primarily ANDAs, rather than biosimilar applications.

What is the most promising new Depakote formulation?

A taste-masked, delayed-release multiparticulate product with flexible dosing and feeding-tube compatibility has the clearest differentiation potential.

Can an excipient change support a 505(b)(2) application?

Yes. A formulation with a meaningful delivery, tolerability or administration improvement may support a 505(b)(2) strategy, subject to FDA requirements and the extent of reliance on existing findings.

References

1. U.S. Food and Drug Administration. (2024). Depakote prescribing information. AbbVie Inc.

2. U.S. Food and Drug Administration. (2024). Inactive ingredient database. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards and patent certifications. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. Center for Drug Evaluation and Research.